No Data
No Data
Express News | Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (Esmo) Breast Cancer Annual Congress
Arvinas Is Maintained at Overweight by Wells Fargo
Arvinas Is Maintained at Overweight by Wells Fargo
Express News | Arvinas Inc : Wells Fargo Cuts Target Price to $60 From $63
Buy Rating Affirmed on Arvinas With Promising Trial Updates and Robust Financial Outlook
Arvinas, Inc. (NASDAQ:ARVN) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Arvinas, Inc. (NASDAQ:ARVN) last week reported its latest first-quarter results, which makes it a good time for investors to dive in and see if the business is performing in line with expectations.
Analysts Offer Insights on Healthcare Companies: Inogen (INGN), Arvinas Holding Company (ARVN) and UniQure (QURE)